Literature DB >> 477009

Hallervorden-Spatz disease.

B R Elejalde, M M de Elejalde, F Lopez.   

Abstract

We had the opportunity to study a family, five of whose members were affected by the Hallervorden-Spatz disease (three males and twin girls). The characteristics of the condition were analyzed and compared with those cases considered by other authors to be affected by the condition. Intrafamilial and interfamilial variations were analysed, and it was the latter that contributed most to the overall variation of the condition. It was clearly established from the reported cases and our family that this is an autosomal recessive condition (P greater than 0.23 +/- 0.08). It is suggested that the condition probably originated in Europe and that it is caused by an inborn error of metabolism related to neuromelanin and the dopaminergic system. The condition affects the muscular tone and voluntary movements progressively, making voluntary coordinated movements, and chewing and swallowing almost impossible, and in the last part of its development mental deterioration, emaciation, severe feeding difficulties and visual impairment are common clinical manifestations. The ages of both onset and death are distributed in a unimodal curve. The mean survival time after diagnosis was 11.18 +/- 7.8 years.

Entities:  

Mesh:

Year:  1979        PMID: 477009     DOI: 10.1111/j.1399-0004.1979.tb00842.x

Source DB:  PubMed          Journal:  Clin Genet        ISSN: 0009-9163            Impact factor:   4.438


  3 in total

1.  Hallervorden-Spatz disease: clinical and MRI study of 11 cases diagnosed in life.

Authors:  L Angelini; N Nardocci; V Rumi; C Zorzi; L Strada; M Savoiardo
Journal:  J Neurol       Date:  1992-10       Impact factor: 4.849

2.  Increased iron content in the putamen of patients with striatonigral degeneration.

Authors:  S Kato; S Meshitsuka; E Ohama; J Tanaka; J F Llena; A Hirano
Journal:  Acta Neuropathol       Date:  1992       Impact factor: 17.088

3.  Iron uptake by glial cells.

Authors:  K F Swaiman; V L Machen
Journal:  Neurochem Res       Date:  1985-12       Impact factor: 3.996

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.